MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Net loss
Proceeds from exercise of tranch...
Proceeds from the maturity and r...
Stock-based compensation expense
Negative Cash Flow Breakdown
Changes in fair value of the war...
Purchase of marketable securitie...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total expenses
-
-
4,981,589
10,121,381
Loss from operations
-
-
-4,981,589
-10,121,381
Foreign exchange losses
-
-
-20,823
-35,732
Investment income
-
-
546,523
401,599
Loss on issuance of convertible preferred stock and warrants
-
-
321,499,041
-
Warrant issuance cost
-
-
3,102,649
-
Changes in fair value of the warrant liability
-
-
-45,389,916
-
Net loss
17,466,285
-125,404,384
-283,667,663
-2,743,954
Depreciation and amortization
-
-
1,360
1,361
Accretion of marketable securities
397,733
136,741
-
-
Stock-based compensation expense
2,272,840
8,710,302
459,028
272,897
Loss on issuance of convertible preferred stock and warrants
-
-
321,499,041
-
Warrant issuance cost
-
-
3,102,649
-
Changes in fair value of the warrant liability
-27,553,204
109,360,630
-45,389,916
-
Prepaid expenses and other current assets
3,402,464
218,488
64,143
433,918
Accounts payable
-693,740
1,465,073
-275,228
-72,739
Accrued expenses and other current liabilities
-1,036,805
796,544
-145,868
60,255
Net cash used in operating activities
-13,344,821
-5,427,064
-4,480,740
-2,916,098
Purchase of marketable securities
9,833,225
45,294,104
-
-
Proceeds from the maturity and redemption of marketable securities
5,000,000
-
-
-
Net cash used in investing activities
-4,833,225
-45,294,104
0
0
Proceeds from sales of common stock and warrants in private placement
-
-
80,000,000
-
Proceeds from exercise of tranche a warrants
10,500,000
1,200,000
-
-
Costs paid in connection with private placements
104,320
90,875
5,348,145
45,166
Payment of deferred offering costs
225,318
30,000
155,948
-
Net cash provided by financing activities
10,170,362
1,079,125
74,495,907
-45,166
Net decrease in cash, cash equivalents and restricted cash
-8,007,684
-49,642,043
70,015,167
-2,961,264
Beginning of period
32,759,770
82,401,813
12,386,646
21,462,008
End of period
24,752,086
32,759,770
82,401,813
12,386,646
Cash and cash equivalents
24,652,086
-
-
-
Restricted cash
100,000
-
-
-
Total cash, cash equivalents and restricted cash
24,752,086
-
-
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
tranche a warrants
$10,500,000
Net cash provided by
financing activities
$10,170,362
Canceled cashflow
$329,638
Net decrease in
cash, cash...
-$8,007,684
(-30.97%↓ Y/Y)
Canceled cashflow
$10,170,362
Net loss
$17,466,285
(349.11%↑ Y/Y)
Stock-based compensation
expense
$2,272,840
(281.70%↑ Y/Y)
Proceeds from the
maturity and redemption...
$5,000,000
Payment of deferred
offering costs
$225,318
Costs paid in
connection with private...
$104,320
Net cash used in
operating activities
-$13,344,821
(-118.26%↓ Y/Y)
Canceled cashflow
$19,739,125
Net cash used in
investing activities
-$4,833,225
Canceled cashflow
$5,000,000
Changes in fair value of
the warrant...
-$27,553,204
Prepaid expenses and
other current assets
$3,402,464
(660.28%↑ Y/Y)
Accrued expenses and
other current...
-$1,036,805
(-357.23%↓ Y/Y)
Accounts payable
-$693,740
(2.43%↑ Y/Y)
Accretion of marketable
securities
$397,733
Purchase of marketable
securities
$9,833,225
Buy us a coffee
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)